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ABSTRACT
Overexpression of HER2 in estrogen receptor (ER)-
positive human breast tumors has been associated with re-
sistance to endocrine therapy. Here we investigated the ef-
fects of HER2 on expression of apoptotic pathways and
modulation of tamoxifen-induced apoptosis in ER-positive
MCF-7 breast cancer cells. We report that HER2 overex-
pression in MCF-7 cells is accompanied by up-regulation of
antiapoptotic Bcl-2 and Bcl-X1 proteins and suppression of
tamoxifen-induced apoptosis. In addition, human tumor cell
lines that are both ER positive and overexpress HER2 also
express enhanced levels of Bcl-2 compared to cells that are
either ER positive or overexpress HER2 alone. Our findings
suggest that possible deregulation of antiapoptotic Bcl-2 and
Bcl-X1 may be associated with the enhanced survival of
HER2-overexpressing and ER-positive breast cancer cells
treated with antiestrogens.
INTRODUCTION
Breast cancer is the second leading cause of cancer death in
women in the United States. A number of studies have demon-
strated that about one-third of breast cancer patients respond to
endocrine therapy, and this population is usually ER3 positive
(I). Despite the presence of ER, a significant proportion of
patients do not respond to hormone therapy. One potential
mechanism for development of resistance to antiestrogen ther-
apy is the influence of growth factor pathways such as HER2
(also known as c-erh-B2 or c-neu). The HER2 encodes a Mr
1 85,000 transmembrane receptor tyrosine kinase glycoprotein
(2) that has been shown to be overexpressed and/or amplified in
breast cancer (3). In vitro studies have shown the development
of tamoxifen resistance in ER-positive MCF-7 human breast
cancer cells upon overexpression of the HER2 gene product (4).
Clinical studies also demonstrated that the overexpression of
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HER2 in ER-positive breast tumors is associated with a de-
creased response to hormone treatment (5. 6). The biochemical
mechanism leading to tamoxifen resistance of ER-positive
breast cancer cells is not well understood.
Programmed cell death, or apoplosis, is a physiological
mechanism of cell death that is dependent on both preexisting
proteins and de nos’o protein synthesis (7, 8). Apoptosis plays an
important role during development, metamorphosis, organ in-
volution, and in many diseases including cancer (8). Apoptosis
is characterized by nuclear condensation and fragmentation and
degradation of DNA into oligonucleosome fragments (7, 8).
Regulation of apoptosis is a complex process and involves a
number of genes including Bcl-2, Bcl-X, Box, and related family
members (7-10). Bcl-2 encodes a protein that protects cells
against apoptosis (7). The Bel-X gene gives rise to two distinct
mRNAs by differential splicing that encode Bdl-XL and Bcl-X
proteins (9). Bcl-XL is related to Bcl-2 in inhibiting apoplosis; in
contrast, Bdl-X is a dominant-negative inhibitor of both Bcl-2
and Bdl-XL (9). Bax is another protein with apoptosis-promot-
ing function and forms homodimers and heterodimers with
Bel-2 ( 10). It is being proposed that the Bcl-2:Bax ratio may be
important in regulating the nature of the apoptotic response; if
Bax predominates, apoptosis is accelerated, and the antiapop-
totic activity of Bcl-2 is antagonized (9, 10). The significance of
expression of Bcl-2 and related family members in human breast
cancer cells is not well defined, as yet. Bcl-2 may play a role in
breast cancer development because this protein is overexpressed
in 70% of breast cancers ( 1 1 ). Recent studies using immunocy-
tochemical staining have shown an inverse relationship between
the levels of Bcl-2 and HER2 expression (12, 13). Breast cancer
MCF-7 cells express easily detectable levels of both Bcl-2 and
Bdl-XL (14, 15). Furthermore, up-regulation of Bcl-2 in MCF-7
breast cancer cells has been shown to be associated with resist-
ance to tamoxifen (1-10 p.M)-induced apoptosis (16).
Since overexpression of Bcl-2 and Bdl-XL in cancer cells
has been shown to result in suppression of apoptosis in response
to a number of anticancer drugs (7, 8, 15, 17), these observations
suggest that cancer cells may depend on Bcl-2 and/or Bdl-XL or
related members to prevent apoplosis, and that deregulation of
apoptotie pathway(s) may modulate the sensitivity of breast
cancer cells to therapeutic agents such as tamoxifen. In the
studies presented here, we investigated the possible role of
HER2 overexpression on apoplotic pathways and modulation of
sensitivity of ER-positive breast cancer cells to tamoxifen-
induced apoplosis using MCF-7 cells as a model system. We
report that HER2 overexpression is accompanied by up-regula-
lion of Bel-2 and Bdl-XL, as well as suppression of tamoxifen-
induced apoptosis in MCF-7 cells.
MATERIALS AND METHODS
Cell Lines and Cultures. Human breast cancer MCF-7
cells and its clones, MCF-7/neo and MCF-7IHER2-18 cells
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(kindly provided by Dr. C. K. Osborne; MCF-7/neo and MCF-
7/HER2-18 cells have easily detectable levels of ER; Ref. 4),
were maintained in DMEM-F12 (1 : 1) supplemented with 10%
FCS. Other human breast cancer cells (T47-D, ZR-75-R, MDA-
231, SKBR-3, MDA-468, MDA-453, MDA-36l, SKOV-3, and
OVCAR-3) were obtained from the American Type Culture
Collection and were grown in the recommended culture media
containing 10% serum. All experiments were performed with
cells in logarithmic growth phase by controlling the plating
density. When desired, subconfluent (about 50% or less conflu-
ent) cells were cultured in phenol red-free DMEM-F1 2 (1:1)
supplemented with 5% charcoal-dextran-treated FCS for 24 h
before tamoxifen treatment. Exponentially growing cells treated
with the desired agents were used to prepare cell extracts as
described (18, 19).
Western Immunoblotting. Cell lysates containing an equal
amount of total protein (15-25 jag) were resolved on a SDS-
PAGE, followed by transfer onto nitrocellulose (18, 19). Mem-
branes were blocked in 1% BSA in TBS, followed by probing
with either anti-Bcl-2 mAb (clone 124; Dako Corp.) or anti-
Bcl-X mAb (20) or anti-Bax-polyclonal (Santa Cruz), and im-
mune complexes were detected by using a secondary antibody-
based alkaline phosphatase color reaction or 1251-labeled protein
A or the ECL method (for detection of Bax; Ref. 18). As an
internal control, the blot was always cut into two pieces after
transfer of proteins. The lower portion of the blot was probed
with a specific antibody, and upper portion was probed with an
unrelated actin antibody (Sigma Chemical Corp.). Low-molec-
ular-mass colored markers (Amersham Corp.) were used as
standards. For reprobing the blots, a nitrocellulose filter was
stripped in 0. 1 M glycine buffer (pH 2.5) for 1 h and neutralized
in 1 M Tris-Cl, pH 8.0 (18). The quantitation of specific protein
bands was performed by using a protein database scanner (Mo-
lecular Dynamics).
Quantitation of Apoptosis. To measure apoptotic cell death,
we used a “cell death” ELISA (Boehringer Mannheim, Indian-
apolis, IN) that measures cyloplasmic DNA-histone complexes
generated during apoptotic DNA fragmentation but not free
histone or DNA that may be generated during nonapoptolic cell
death (14-16). MCF-7 cells (2 X 10) were plated into each
well of a 48-well plate. After the desired treatment, the cells
were washed with PBS, and cytoplasmic extracts were made
from both adherent and nonadherent cells, according to the
manufacturer’s protocol. Control and tamoxifen-treated cell ex-
tracts were equalized on the basis of equal cell number, as well
as protein in the extracts. Briefly, cells were first coated with
anti-histone antibody, loaded with cytoplasmic extracts, and
followed by incubation with anti-DNA second antibody conju-
galed with peroxidase. ELISA was developed with peroxidase
substrate, and the absorbance at 405 nm was measured using the
Microplale autoreader; results are presented as the fold increase
over control untreated cells.
RESULTS
Expression of Bcl-2 in Human Breast Cancer Cell
Lines. To examine the possible relationship between HER2
and ER and apoptotic pathway(s) in human breast cancer cells,
we determined the expression of Bcl-2 in a panel of breast
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Fig. 1 Expression of Bcl-2 in human breast cancer cell lines. Expo-
nentially growing cells were used to prepare cell extracts. Aliquots
containing equal amounts of protein (50 p.g) were resolved onto a 10%
SDS-PAGE. Proteins were transferred to nitrocellulose, immunoblotted
with an anti-Bcl-2 mAb, and visualized using an alkaline phosphatase
color system. In A, the same blot was cut into two pieces, and upper
panel Al was blotted with unrelated antibody to show the relative
amount of nonspecific proteins in different lanes. In B, cell extracts from
ovarian cell lines were immunoblotted with an anti-BcI-2 mAb.
Table 1 Summary of Bcl-2 expression in breast cell lines
Bcl-2 expression#{176} Cell lines
+ + + + ZR-75-R, BT-474
+ + MDA-23 1, MDA-468, MCF-7
+ T-47-D, BT-20, SK-BR-3
0
a Bcl-2 levels from immunoblot in Fig. I , semiquantitative manner.
cancer cell lines using a anti-Bel-2 mAb in Western immuno-
blotting. All the cell lines we tested have easily detectable levels
of Bcl-2 expression (Fig. 1 and Table 1 ). Results indicated that
there was no significant difference in the levels of Bel-2 be-
tween ER-positive cells, such as MCF-7 and T47-D, and HER2-
overexpressing cells, such as SKBR-3 and MDA-453. In con-
trast, it was interesting to note that ER-positive cells with HER2
overexpression, such as ZR-75-R and BT-474, demonstrated a
significantly higher (2-5-fold) levels of Bcl-2 protein. This
pattern of Bcl-2 expression was also observed in human ovarian
cancer cells as OVCAR-3 cells (ER positive and overexpressing
HER2) express a higher levels of Bel-2 than SKOV-3 cells
(HER2 overexpressing).
Effect of HER2 Overexpression on the Levels of Bcl-2
in MCF.7 Cells. The results in Fig. 1 suggest that the over-
expression of HER2 in ER-positive breast cancer cells is asso-
cialed with increased Bcl-2 expression. To further test this
hypothesis, we used MCF-7 cells stably transfected with human
HER2 (MCF-7/HER2-1 8 cells express 45 times the increased
HER2 levels; Ref. 4) or control mock neo vector-transfected
cells (MCF-7/Neo cells; Ref. 4). Results in Fig. 2A show that
HER2 overexpression in MCF-7 cells (Fig. 14, Lane 3) lead to
up-regulation (2.5-6-fold; n = 8) in the levels of Bcl-2 com-
pared to the levels in the parental (Fig. 14, Lane 1) or moek/
neo-transfeeted (Fig. 2A, Lane 2) MCF-7 cells. Data in Fig. 2, B
and C, demonstrated that HER2 overexpression in MCF-7/
HER2-l8 cells (Fig. 2B) was associated with enhanced Bcl-2
expression. There was no effect of HER2 overexpression on the
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Fig. 2 Effect of HER2 on the levels of Bcl-2 in MCF-7 cells. A.
exponentially growing cells were used to examine the Bcl-2 expression
in different MCF-7 clones. Aliquots containing equal amounts of protein
(20 p.g) were resolved onto a 15% SDS-PAGE, irnmunoblotted with a
anti-Bcl-2 mAb, and visualized using an alkaline phosphatase color
system. Lane 1, control MCF-7 cells; Lane 2. MCF-7/Neo cells: Lane 3.
MCF-7/HER2-18 cells. B, overexpression of HER2 in MCF-7 cells.
Labeled cell lysates from MCF-7fNeo cells (Lane 1) and MCF-7/
HER2-18 cells (Lane 2) were irnrnunoprecipitated with an anti-HER2
mAb 9G6 and resolved on a 7% SDS-PAGE. C, cell extracts from
MCF-7fNeo cells (Lane 1) and MCF-7/HER2-18 cells (Lane 2) were
resolved on 12% SDS-PAGE, imrnunoblotted with an anti-Bcl-2 mAb
(upper panel), and followed by sequential reprobing with anti-actin Ab
(loner panel).
A. B.
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Fig. 3 Effect of HER2 on the levels of Bcl-X and Bax in MCF-7 cells.
A. cell extracts ( 15 p.g) from MCF-7INeo cells (Lanes / and 3) and
MCF-7/HER2-l8 cells (Lanes 2 and 4) were resolved on a 12% SDS-
PAGE and immunoblotted with an anti-BcI-X mAb. Lanes I and 2 and
Lanes 3 and 4 are from two different experiments. B. cell extracts from
MCF-7fNeo (Lane /) and MCF-7/HER2-18 (Lane 2) were irnrnuno-
blotted with anti-Bax Ab (upperpanel), followed by sequential reprob-
ing with anti-BcI-mAb.
levels of an unrelated proteins such as adtin (Fig. 2C) and
2-5(A)synthetases (data not shown). In addition to Bcl-2 pro-
tein, the anti-Bcl-2 mAb used here cross-reacted with an addi-
tional protein in MCF-7/HER2-18 cells (Fig. 2C. Lane 2, see
band under the Bcl-2) and will be investigated as a part of
another study.
Effect of HER2 Overexpression on the Levels of Bcl-X
and Bax in MCF-7 Cells. Since apoptosis in mammalian cells
is also regulated by Bcl-X gene products, we examined expres-
sion of Bcl-XL and Bel-X5 in MCF-2fNeo and MCF-7/
HER2-18 cells using a well characterized anti-Bcl-X mAb that
recognizes both Bdl-XL and Bdl-X (20). Results in Fig. 3A
indicated that HER2 overexpression in MCF-7 cells also lead to
enhanced expression of Bdl-XL with no change in the levels of
Bel-X5. We also examined the expression of Bcl-XL in other
breast cancer cell lines, and results indicated that the relative
levels of Bdl-XL were 3-fold higher in BT-474 cells (HER2-
overexpressing. ER-positive cells) compared to SK-BR-3
(HER2-overexpressing cells) or MCF-7 (ER-positive cells; data
not shown).
Since it has been proposed that the ratio of Bax to Bcl-2 or
Fig. 4 Effect of HER2 on tarnoxifen-induced apoptosis in MCF-7
cells. Expression of Bdl-XL in breast cancer cells. Cells were grown in
estrogen-free medium for 24 h and then treated with or without tarnox-
ifen ( 106 or l0 M) for 24 h. Cell extracts were made, and induction
of apoptosis was determined by quantitative ELISA. Columns. mean:
bars, SE (ii = 3).
Bdl-XL may be important in regulating apoptolic response (10)
and the fact that reduced Bax expression has been correlated
with the poor response to chemotherapy (2 1 ), we examined the
effect of HER2 overexpression on the levels of Bax. Results in
Fig. 3B indicated that there was no significant change in the
expression of Bax between MCF-7/Neo (Fig. 3B, Lane 1) and
MCF-7/HER2-18 cells (Fig. 3B, Lane 2).
Effect of HER2 Overexpression on Apoptosis in MCF-7
Cells. Since HER2 overexpression in MCF-7/HER2-1 8 cells
increases antiapoplolic Bcl-2 and Bdl-XL, we examined whether
overexpression of HER2 will modulate apoptosis. To test this
possibility. we examined the sensitivity of MCF-7 cells with or
without HER2 overexpression to undergo apoptosis in response
to tamoxifen. Results in Fig. 4 show that HER2 overexpression
is associated with significant suppression in the tamoxifen-
induced stimulation of apoplosis because there was up to I .8 ±
0.4 (n = 3) fold increase in apoptosis in MCF-7/HER2-18 cells
compared to 3.8 ± 0.63 (ii = 3) fold in MCF-7/Neo cells by
24-h tamoxifen (10 M) treatment.
DISCUSSION
It is generally recognized that the expression of HER2 in
ER-positive breast cancer cells leads to development of resist-
ance to endocrine therapy (4-6). In recent years, apoptosis has
emerged as a physiological mechanism of cell death in response
to a variety of chemotherapy drugs and hormones. including
tamoxifen (16. 17). Overexpression of antiapoptotic proteins
such as Bel-2 and Bdl-XL has been shown to result in the
reduced sensitivity of a number of human cell lines to cytotoxid/
inhibitory effects of chemotherapy drugs (7. 8, 13, 17). There-
fore, deregulation of apoptolic pathways could constitute one of
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the potential mechanisms of resistance to tamoxifen, a phenom-
enon generally associated with HER2 overexpression in ER-
positive cells (4-6). To explore this hypothesis, we investigated
the effect of HER2 overexpression on apoplotic pathways in
MCF-7 cells.
The results presented here demonstrate that overexpres-
sion of HER2 in MCF-7 cells results in increased expression
(2-5-fold) of Bcl-2 and Bcl-XL and suppression of tamox-
ifen-induced apoptosis compared to cells transfected with
neo vector alone. Our observation of enhanced Bcl-2 expres-
sion in HER2 overexpressing (also ER-positive) breast can-
cer cells is apparently not consistent with the reports from the
literature showing an inverse correlation between HER2 and
Bcl-2 expression (12 13). In this regard, it is important to
note that those studies (12, 13) have correlated the levels of
Bcl-2 with the individual expression of HER2 or ER and not
with the co-overexpression of HER2 in ER-positive breast
cancer cells. In addition, there may be other important dif-
ferences between the methods in those Iwo studies ( I 2, 13)
that used immunochemical method rather than physical de-
teclion of the Mr 26,000 Bc1-2 protein used in our study. In
this context, it is worth noticing that the anti-Bcl-2 mAb
(clone 124; Dako) used in immunocytochemical studies (12,
I 3) cross-reacts with proteins other than the Mr 26,000 Bel-2
in MCF-7/HER2-18 cells (Fig. 2C, see band under Bcl-2)
and also in human colorectal carcinoma DiFi cells (data not
shown). Moreover, Teixeira el a!. (22) have recently reported
the cross-reactivity of both polyclonal and monoclonal anti-
Bcl-2 antibodies, with an additional Mr 28,000 protein in
MCF-7 cells (22). The finding that HER2 overexpression did
not influence the levels of proapoptotic Bax and only en-
hanced the levels of Bcl-2 and Bcl-XL suggests that HER2
overexpression in MCF-7 cells may shift the Bdl-2:Bd1-XL
ratio to Bax toward suppression of apoptosis as demonstrated
in this study. In this context, it is important to note that,
recently, enhancement in the levels of Bcl-2 has been shown
to confer resistance to lamoxifen-induced apoplosis in
MCF-7 cells (16). Because Bcl-2 and Bcl-XL are antiapop-
totic proteins, the observed resistance of tamoxifen-induced
apoptosis in HER2-overexpressing MCF-7 cells may have a
close relationship with enhanced expression of Bcl-2 and
Bc1-XL.
Our finding of enhanced expression of Bcl-2 and Bdl-XL in
MCF-7/HER2-l8 cells have raised a number of new issues
regarding the mechanism(s) of regulation of antiapoptotic gene
products in ER-positive breast cancer cells and its modulation
by HER2. Why is enhanced expression of Bcl-2 and Bcl-XL
restricted to HER2-overexpressing, ER-positive breast cancer
cells? Is there any contribution of regulatory interaction(s) be-
tween HER2 and ER? The mechanism by which co-overexpres-
sion of HER2 in ER-positive breast cancer cells influences the
levels of antiapoplotic proteins remains to be determined. This
may occur at the transcriptional level and/or posltranscriptional
level and may also involve enhanced mRNA stability, leading to
an increase in protein expression. Our findings support the
hypothesis of possible deregulation of apoptotic pathways
and up-regulation of antiapoptotic Bcl-2 and Bcl-XL in breast
cancer cells; these biochemical changes may lead to en-
hanced survival of HER2-overexpressing, ER-positive cells
upon endocrine therapy and thus could play a role(s) in breast
cancer progression.
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